维普期刊资源整合服务平台（V6.5）

34篇 您的检索式：作者名="Cremolini C"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer:updated overall survival and molecular subgroup analyses of the open-label,phase 3 TRIBE study 显示文摘	Cremolini C Loupakis F Antoniotti C	2015	Lancet Oncol2015，16，13：	1
2	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab显示文摘	Loupakis F Cremolini C Yang D	2013	PLo S One2013，8，66：	1
3	Early tumour shrinkage as a prognostic factor and surrogate end - point in colorectal cancer: A systematic review and pooled - analysis显示文摘	Petrelli F Pietrantonio F Cremolini C	2015	Eur J Cancer2015，51，7：	1
4	KRAS codon61,146 and BRAF mutations predict resistance to cetu-ximab plus irinotecan in KRAS codon 12 and 13 wild-typemetastatic colorectal cancer显示文摘	Loupakis F Ruzzo A Cremolini C	2009	Br J Cancer2009，101，4：	1
5	Clinical impact of anti - epidermal growth factor receptor monoclonal an- tibodies in first - line treatment of metastatic colorectal cancer显示文摘	LOUPAKIS F CREMOLINI C SALVATORE L	2012	Cancer2012，118，6：	1
6	FOLFOXIRI/bevacizum- ab (bey) versus FOLFIRI/bev as first-line treatment in unresect- able metastatic colorectal cancer (mCRC) patients (pts) : Results of the phase Ⅲ TRIBE trim by GONO group 显示文摘	Faocone A Cremolini C Masi G	2013	J Clin Oncol2013，，：	1
7	FOLFOXIRI/bevacizumab(bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts):Results of the phase Ⅲ TRIBE trial by GONO group显示文摘	Falcone A Cremolini C Gianluca M	2013	J Clin Oncol2013，31，15：	1
8	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 显示文摘	Loupakis F Cremolini C Masi G	2014	N EnglJ Med2014，371，17：	1
9	Predictors of benefit in colorectal cancer treated with cetuximab:are we getting 'Lost in TranslationAL'显示文摘	Cremolini C Loupakis F Ruzzo A	2010	J Clin Oncol2010，28，11：	1
10	KRAS codon 61,146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild - type metastatic colorectal cancer 显示文摘	Loupakis F Ruzzo A Cremolini C	2009	Br J Cancer2009，101，：	1
11	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer显示文摘	Loupakis F Cremolini C Salvatore L	2014	Eur J Cancer2014，50，：	1
12	First-line anti- EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and recta-analysis 显示文摘	Pietrantonio F Cremolini C Petrelli F	2015	Crit Rev Oncol Hematol2015，96，1：	1
13	Initial therapy with FOLFOXIRI and bevacizumab for metastatic eolorectal cancer显示文摘	LOUPAKIS F CREMOLINI C MASI G	2014	N Engl J Med2014，，：	1
14	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer显示文摘	LOUPAKIS F CREMOLINI C MASI G	2014	N Engl J Med2014，371，17：	1
15	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer显示文摘	Loupakis F Cremolini C Masi G	2014	N Engl J Med2014，371，17：	1
16	FOLFOXIRI/ bevacizumab(bev)versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer(mCRC)patients(pts):Results of the phase Ⅲ TRIBE trial by GONO group MD显示文摘	FALCONE A CREMOLINI C MASI G	2013	J Clin Oncol2013，31，15：	1
17	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 显示文摘	Loupakis F Cremolini C Masi G	2014	N Engl J Med2014，371，17：	1
18	KRAS codon 61, 146and BRAF mutations predict resistance to cetuximab plusirinotecan in KRAS codon 12 and 13 wild-type metastaticcolorectal cancer显示文摘	Loupakis F Ruzzo A Cremolini C	2009	Br J Cancer2009，101，4：	1
19	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer:updated overall survival and molecular subgroup analyses of the open-label,phase3 TRIBE study显示文摘	Cremolini C Loupakis F Antoniotti C	2015	Lancet Oncol2015，16，13：	1
20	Subgroup analyses in RAS mutant,BRAF mutant and all-wt mC RC pts treated with FOLFOXIRI plus bevacizumab(bev)or FOLFIRI plus bev in the TRIBE study显示文摘	Loupakis F Cremolini C Lonardi S	2014	J Clin Oncol2014，32，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示